Nautilus Biotechnology (NAUT) EPS (Weighted Average and Diluted) (2020 - 2026)
Nautilus Biotechnology has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.12 for Q1 2026.
- Quarterly results put EPS (Weighted Average and Diluted) at -$0.12 for Q1 2026, up 7.69% from a year ago — trailing twelve months through Mar 2026 was -$0.46 (up 14.81% YoY), and the annual figure for FY2025 was -$0.47, up 16.07%.
- EPS (Weighted Average and Diluted) reached -$0.12 in Q1 2026 per NAUT's latest filing, down from -$0.11 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.1 in Q4 2022 and bottomed at -$0.15 in Q1 2024.
- Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.13 (2022), compared with a mean of -$0.13.
- The largest annual shift saw EPS (Weighted Average and Diluted) surged 48.0% in 2022 before it plummeted 40.0% in 2023.
- Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.1 in 2022, then tumbled by 40.0% to -$0.14 in 2023, then fell by 0.0% to -$0.14 in 2024, then grew by 21.43% to -$0.11 in 2025, then dropped by 9.09% to -$0.12 in 2026.
- Business Quant data shows EPS (Weighted Average and Diluted) for NAUT at -$0.12 in Q1 2026, -$0.11 in Q4 2025, and -$0.11 in Q3 2025.